Silence Therapeutics Plc - American Depository Share (SLN)
5.5000
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 5th, 5:49 AM EDT

Via Benzinga · June 3, 2025
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via Chartmill · April 1, 2025

Via Benzinga · March 4, 2025

Via Benzinga · February 3, 2025

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Via Talk Markets · February 15, 2025

Via Benzinga · February 11, 2025

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Via Benzinga · November 19, 2024

Via Benzinga · May 17, 2024

Via Benzinga · April 22, 2024

Silence Therapeutics just reported results for the second quarter of 2024.
Via InvestorPlace · August 15, 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via InvestorPlace · August 7, 2024

It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via InvestorPlace · July 25, 2024

Silence Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · May 16, 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via InvestorPlace · April 11, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via InvestorPlace · March 18, 2024

Via Benzinga · March 13, 2024

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.
Via Benzinga · March 14, 2024